PharmaEngine, Inc. (TPEX:4162)
Taiwan · Delayed Price · Currency is TWD 53.60
+0.60 (1.13%)
May 29, 2026, 1:30 PM CST
PharmaEngine Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 963.83 | 911.42 | 2,523 | 767.67 | 654.38 | 654.84 | |
Revenue Growth (YoY) | -62.15% | -63.88% | 228.70% | 17.31% | -0.07% | -37.99% |
Cost of Revenue | 54.7 | 51.85 | 47.74 | 48.7 | 49.7 | 37.07 |
Gross Profit | 909.13 | 859.56 | 2,476 | 718.97 | 604.68 | 617.76 |
Selling, General & Admin | 133.85 | 134.37 | 155.37 | 131.51 | 140.06 | 118.4 |
Research & Development | 308.69 | 299.72 | 267.03 | 310.28 | 181.88 | 136.89 |
Operating Expenses | 442.56 | 434.1 | 422.4 | 441.79 | 321.95 | 255.07 |
Operating Income | 466.57 | 425.46 | 2,053 | 277.18 | 282.74 | 362.69 |
Interest Expense | -0.32 | -0.14 | -0.18 | -0.31 | -0.08 | -0.21 |
Interest & Investment Income | 99.28 | 96.1 | 72.14 | 54.32 | 25.57 | 15.42 |
Currency Exchange Gain (Loss) | -12.24 | -12.24 | 37.66 | -2.13 | 8.8 | -15.68 |
Other Non Operating Income (Expenses) | -1.15 | 0.11 | 0.21 | - | 0.03 | 0.31 |
EBT Excluding Unusual Items | 552.13 | 509.29 | 2,163 | 329.06 | 317.06 | 362.53 |
Gain (Loss) on Sale of Investments | - | - | - | 5.53 | 45.46 | 0.82 |
Other Unusual Items | - | - | - | 3.39 | 29.95 | 182.04 |
Pretax Income | 552.13 | 509.29 | 2,163 | 337.97 | 392.47 | 545.4 |
Income Tax Expense | 129.58 | 121.65 | 411.97 | 63.32 | 73.68 | 119.36 |
Net Income | 422.55 | 387.64 | 1,751 | 274.65 | 318.78 | 426.03 |
Net Income to Common | 422.55 | 387.64 | 1,751 | 274.65 | 318.78 | 426.03 |
Net Income Growth | -76.15% | -77.86% | 537.55% | -13.84% | -25.17% | -29.50% |
Shares Outstanding (Basic) | 144 | 144 | 144 | 144 | 144 | 145 |
Shares Outstanding (Diluted) | 144 | 144 | 144 | 144 | 144 | 145 |
Shares Change (YoY) | -0.20% | 0.01% | 0.13% | 0.03% | -0.72% | -0.80% |
EPS (Basic) | 2.94 | 2.70 | 12.19 | 1.91 | 2.22 | 2.95 |
EPS (Diluted) | 2.94 | 2.69 | 12.17 | 1.91 | 2.22 | 2.94 |
EPS Growth | -76.13% | -77.90% | 537.17% | -13.96% | -24.49% | -28.99% |
Free Cash Flow | 178.19 | 1,727 | 455.92 | 256.56 | 198.57 | 929.44 |
Free Cash Flow Per Share | 1.24 | 11.99 | 3.17 | 1.78 | 1.38 | 6.42 |
Dividend Per Share | 2.000 | 2.000 | 6.000 | 1.500 | 2.000 | 2.700 |
Dividend Growth | -66.67% | -66.67% | 300.00% | -25.00% | -25.93% | 8.00% |
Gross Margin | 94.32% | 94.31% | 98.11% | 93.66% | 92.41% | 94.34% |
Operating Margin | 48.41% | 46.68% | 81.37% | 36.11% | 43.21% | 55.39% |
Profit Margin | 43.84% | 42.53% | 69.39% | 35.78% | 48.72% | 65.06% |
Free Cash Flow Margin | 18.49% | 189.44% | 18.07% | 33.42% | 30.34% | 141.94% |
EBITDA | 468.71 | 427.21 | 2,055 | 278.55 | 283.44 | 363.39 |
EBITDA Margin | 48.63% | 46.87% | 81.43% | 36.29% | 43.31% | 55.49% |
D&A For EBITDA | 2.14 | 1.75 | 1.65 | 1.37 | 0.71 | 0.7 |
EBIT | 466.57 | 425.46 | 2,053 | 277.18 | 282.74 | 362.69 |
EBIT Margin | 48.41% | 46.68% | 81.37% | 36.11% | 43.21% | 55.39% |
Effective Tax Rate | 23.47% | 23.89% | 19.05% | 18.74% | 18.77% | 21.89% |